Company profile
ASTRAZENECA PLC
NYSE:AZNBiotechnology: Pharmaceutical Preparations
Drug pipeline (227)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Acalabrutinib | approved | — | 17 | approved |
| Acalabrutinib maleate anhydrous | approved | — | 0 | — |
| Albuterol Sulfate | approved | — | 3 | approved |
| AMITRIPTYLINE HYDROCHLORIDE | approved | — | 0 | — |
| ANASTROZOLE | approved | — | 32 | approved |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (2926)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT00673205 | phase3 | completed | 1995-09-01 | 2008-08-01 | AstraZeneca | (Bicalutamide) Casodex vs Placebo in Non-metastatic Early Prostate Cancer |
| NCT00997945 | phase1 | completed | 2009-10-01 | 2010-09-01 | AstraZeneca | 10mg ZD4054 (Zibotentan) PK Study in Male, Elderly Chinese Patients With Advanced Solid Malignancies |
| NCT00525824 | phase3 | completed | 2007-08-01 | 2008-09-01 | AstraZeneca | 12-week Open-label, Phase IIIb Comparing Efficacy and Safety of Rosuvastatin (CRESTOR™) in Combination With Ezetimibe |
| NCT00813306 | phase1_2 | completed | 2008-12-01 | — | AstraZeneca | 14473 - D9126C00001 Proof of Principle Study - Effect of AZD2066 on Transient Lower Esophageal Sphincter Relaxations |
| NCT00766415 | phase2 | completed | 2008-11-01 | — | AstraZeneca | 14729-D9831C00002- 1 Month Biopsy Study |
FDA applications (110)
| Application | Type | Applicant | Products | |||
|---|---|---|---|---|---|---|
| ANDA 070014 | ANDA | ASTRAZENECA LP | ||||
Loading… | ||||||
| ANDA 071018 | ANDA | ASTRAZENECA LP | ||||
Loading… | ||||||
| ANDA 071151 | ANDA | ASTRAZENECA LP | ||||
Loading… | ||||||
| ANDA 071152 | ANDA | ASTRAZENECA LP | ||||
Loading… | ||||||
| ANDA 071153 | ANDA | ASTRAZENECA LP | ||||
Loading… | ||||||